Suspected multiple sclerosis – what to do? Evaluation of a patient information leaflet

Abstract

Background

Parallel to the establishment of early treatments in multiple sclerosis (MS), new diagnostic criteria have made an earlier diagnosis possible. While there is ongoing discussion about possible benign courses and only partial effective treatments, there have been no attempts today to facilitate shared decision making on diagnostic testing between patients with suspected MS and their physicians.

Objective

This study describes the development and validation process of a leaflet to be presented to people with suspected MS to engage them in a diagnostic decision-making process.

Methods

After a qualitative study showing acceptability among five patients, the leaflet was presented to a retrospective cohort (n = 87 of which 70 replied)) of patients being diagnosed within the last 2 years as well to a prospective cohort of n = 51 patients with symptoms suggestive of MS.

Results

Approximately 70% of patients in the prospective as well as in the retrospective cohort wanted to be informed about a possible MS before testing, whereas 10% did not. The leaflet did not seem to elicit anxieties. The attitude to undergo diagnostic testing was not influenced by the leaflet, which can be explained by the nonexperimental design of the study.

Conclusion

Taken together, our findings demonstrate that early information about possible MS is warranted by patients and does not show negative side effects. Further studies on evidence-based patient information in early MS seem necessary.

Keywords

anxieties diagnostic tests evidence based patient information multiple sclerosis shared decision making

Get full access to this article

View all access options for this article.

References

1 McDonald WI Compston A Edan G . Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 2001; 50: 121–127.

2 Polman CH Reingold SC Edan G . Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria". Ann Neurol 2005; 58: 840–846.

3 Clerico M Faggiano F Palace J Rice G Tintorè M Durelli L . Recombinant interferon beta or glatiramer acetate for delaying conversion of the first demyelinating event to multiple sclerosis. Cochrane Database Syst Rev 2008; 16: CD005278.

4 Kinkel RP Kollman C O'Connor P . ; the CHAMPIONS Study Group, et al. IM interferon beta-1a delays definite multiple sclerosis 5 years after a first demyelinating event. Neurology 2006; 66: 678–684.

5 Kappos L Freedman MS Polman CH . ; BENEFIT Study Group, et al. Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study. Lancet 2007; 370: 389–397.

6 Ramsaransing GS De Keyser J . Predictive value of clinical characteristics for 'benign' multiple sclerosis. Eur J Neurol 2007; 14: 885–889.

7 Confavreux C Vukusic S . Natural history of multiple sclerosis: a unifying concept. Brain 2006; 129: 606–616.

9 Schünemann HJ Oxman AD Brozek J . ; the GRADE Working Group, et al. Grading quality of evidence and strength of recommendations for diagnostic tests and strategies. BMJ 2008; 336: 1106–1110.

10.

10 Whiting P Harbord R Main C . Accuracy of magnetic resonance imaging for the diagnosis of multiple sclerosis: systematic review. BMJ 2006; 332: 875–884.

11.

11 Korteweg T Tintoré M Uitdehaag B . MRI criteria for dissemination in space in patients with clinically isolated syndromes: a multicentre follow-up study. Lancet Neurol 2006; 5: 221–227.

12.

12 Gluud C Gluud LL . Evidence based diagnostics. BMJ 2005; 330: 724–726.

13.

13 Windeler J . Prognosis-what does the clinician associate with this notion. Stat Med 2000; 19: 425–430.

14.

14 Heesen C Kasper J Segal J Koepke S Mühlhauser I . Decisional role preferences, knowledge and information interests in patients with multiple sclerosis. Mult Scler 2004; 10: 643–650.

15.

15 Köpke S Kasper J Mühlhauser I Nübling M Heesen C . Patient education program to enhance decision autonomy in multiple sclerosis relapse management: a randomized-controlled trial. Mult Scler 2009; 15: 96–104 Epub 2008 Oct 9.

16.

16 Kasper J Köpke S Mühlhauser I Heesen C . Evidence-based patient information about treatment of multiple sclerosis—a phase one study on comprehension and emotional responses. Patient Educ Couns 2006; 62: 56–63.

17.

17 Heesen C Kolbek J Gold SM Schulz H Schulz KH . Delivering the diagnosis of MS- results of a survey among patients and neurologists. Acta Neurol Scand 2003; 107: 363–368.

18.

18 Whiting P Toerien M de Salis I . A review identifies and classifies reasons for ordering diagnostic tests. J Clin Epidemiol 2007; 60: 981–989.

19.

19 Gray MJ . Problems of evidence-based patient choice in screening programmes. Z Arztl Fortbild Qualitatssich 2006; 100: 494–499.

20.

20 Steckelberg A Berger B Köpke S Heesen C Mühlhauser I . Kriterien für evidenzbasierte Patienteninformationen. Z Arztl Fortbild Qualitatssich 2005; 99: 343–351.

21.

21 McNutt RA . Shared medical decision making: problems, process, progress. JAMA 2004; 292: 2516–2518.

22.

22 Saba GW Wong ST Schillinger D . Shared decision making and the experience of partnership in primary care. Ann Fam Med 2006; 4: 54–62.

23.

23 Holmes-Rovner M . International Patient Decision Aid Standards (IPDAS): beyond decision aids to usual design of patient education materials. Health Expect 2007; 10: 103–107.

24.

24 Someren MW van Barnard YF Sandberg JAC . The think aloud method – a practical guide to modelling cognitive processes. London: Academic Press; 1994.

25.

25 Degner LF Sloan JA Venkatesh P . The control preference scale. Can J Nurs Res 1997; 29: 21–43.

26.

26 Janssens AC de Boer JB Kalkers NF Passchier J van Doorn PA Hintzen RQ . Patients with multiple sclerosis prefer early diagnosis. Eur J Neurol 2004; 11: 335–337.

27.

27 Heesen C Segal J Reich C . Acceptability of patient information on cognitive symptoms in MS. Acta Neurol Scand 2006; 114: 268–272.

28.

28 Janssens AC de Boer JB van Doorn PA . Expectations of wheelchair-dependency in recently diagnosed patients with multiple sclerosis and their partners. Eur J Neurol 2003; 10: 287–293.

29.

29 Janssens AC van Doorn PA de Boer JB van der Meché FG Passchier J Hintzen RQ . Impact of recently diagnosed multiple sclerosis on quality of life, anxiety, depression and distress of patients and partners. Acta Neurol Scand 2003; 108: 389–395.

30.

30 Johnson J . On receiving the diagnosis of multiple sclerosis: managing the transition. Mult Scler 2003; 9: 82–88.

31.

31 Papathanasopoulos PG Nikolakopoulou A Scolding NJ . Disclosing the diagnosis of multiple sclerosis. J Neurol 2005; 252: 1307–1309.